Country |
Opioids |
Cocaine |
Stimulants |
Hypnotics, sedatives |
Hallucinogens |
Volatile inhalants |
Cannabis |
Alcohol |
Others |
Total |
|---|---|---|---|---|---|---|---|---|---|---|
Czech Republic |
2.8 |
3.0 |
2.3 |
2.3 |
9.7 |
1.9 |
2.4 |
2.7 |
0.0 |
637 |
Denmark |
5.9 |
3.3 |
3.4 |
3.1 |
3.0 |
1.3 |
3.5 |
3.9 |
2.2 |
1758 |
Germany |
3.8 |
5.1 |
4.1 |
1.4 |
5.4 |
2.9 |
6.1 |
3.8 |
4.6 |
39616 |
Greece |
3.3 |
5.4 |
6.2 |
5.0 |
8.7 |
5.0 |
6.8 |
12.0 |
7.4 |
1920 |
Italy |
6.6 |
6.5 |
5.7 |
3.8 |
9.8 |
5.1 |
8.6 |
7.6 |
|
34308 |
Cyprus |
3.5 |
10.7 |
3.7 |
2.0 |
0.0 |
0.0 |
9.4 |
0.0 |
0.0 |
117 |
Malta |
3.5 |
5.2 |
3.8 |
0.0 |
0.0 |
0.0 |
6.3 |
|
|
127 |
Netherlands |
6.2 |
3.1 |
3.0 |
1.3 |
1.7 |
0.0 |
4.1 |
4.3 |
1.7 |
2315 |
Slovenia |
2.4 |
2.0 |
15.0 |
7.0 |
0.0 |
|
3.7 |
3.6 |
0.0 |
300 |
Slovakia |
10.5 |
2.0 |
3.1 |
6.0 |
2.8 |
|
4.6 |
2.8 |
|
291 |
Finland |
2.6 |
0.0 |
1.7 |
1.3 |
0.0 |
0.0 |
2.6 |
2.4 |
0.0 |
408 |
Sweden |
1.4 |
5.2 |
5.0 |
1.5 |
5.0 |
|
1.9 |
1.8 |
2.4 |
715 |
United Kingdom |
1.9 |
2.8 |
2.8 |
2.1 |
2.7 |
2.0 |
2.9 |
3.0 |
2.6 |
13816 |
Bulgaria |
2.3 |
3.0 |
5.0 |
2.0 |
0.0 |
0.0 |
12.5 |
|
|
94 |
|
|
|
|
|
|
|
|
|
|
|
Total |
4.0 |
4.8 |
4.0 |
2.4 |
6.6 |
2.6 |
5.9 |
4.2 |
4.0 |
96422 |
Notes: Italy: 90 males and no female cases. Malta: 3 males, no female cases for 'alcohol' and 'other' (blank space). Slovenia, Sweden, Bulgaria: 1 male, no female cases for volatile inhalants and 'other' (blank space). Slovakia, Sweden: 6 males, no female cases for volatile inhalants. Slovakia: 3 males, no female cases for 'other' (blank space). Bulgaria: 3 males, no female cases for 'alcohol' (blank space). Data on secondary drug use are only collected for all treatment clients and not separately for new treatment clients. Opioids include: heroin, methadone, other opioids; cocaine includes: cocaine CIH, crack cocaine; stimulants include: amphetamines, MDMA and derivates, other stimulants. Cannabis can include herbal cannabis or cannabis resin. For each client up to four secondary drugs can be used: therefore the total number of clients does not correspond to the total number of client by country. A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI Protocol for the drugs categories. See also 'General notes for interpreting data' on the Explanatory notes and help page. Source: | ||||||||||